You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

CLINICAL TRIALS PROFILE FOR EFLORNITHINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for EFLORNITHINE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00003076 ↗ Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed National Cancer Institute (NCI) Phase 2 1995-10-01 RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.
NCT00003076 ↗ Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed University of Michigan Cancer Center Phase 2 1995-10-01 RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.
NCT00003076 ↗ Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus Completed University of Michigan Rogel Cancer Center Phase 2 1995-10-01 RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.
NCT00003814 ↗ Eflornithine in Treating Patients With Bladder Cancer Completed National Cancer Institute (NCI) Phase 3 1999-02-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if eflornithine is more effective than no further therapy in treating bladder cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of eflornithine in treating patients who have newly diagnosed or recurrent bladder cancer.
NCT00005882 ↗ Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps Completed Chao Family Comprehensive Cancer Center Phase 3 1998-07-01 This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
NCT00005882 ↗ Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps Completed National Cancer Institute (NCI) Phase 3 1998-07-01 This randomized phase III trial is studying eflornithine and sulindac to see how well they work compared to a placebo in preventing colorectal cancer in patients with colon polyps. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of eflornithine and sulindac may prevent colorectal cancer. It is not yet known whether eflornithine and sulindac are more effective than a placebo in preventing colorectal cancer
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for EFLORNITHINE HYDROCHLORIDE

Condition Name

Condition Name for EFLORNITHINE HYDROCHLORIDE
Intervention Trials
Trypanosomiasis, African 5
Neuroblastoma 4
Prostate Cancer 3
Familial Adenomatous Polyposis 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for EFLORNITHINE HYDROCHLORIDE
Intervention Trials
Trypanosomiasis, African 7
Trypanosomiasis 7
Colorectal Neoplasms 6
Neuroblastoma 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for EFLORNITHINE HYDROCHLORIDE

Trials by Country

Trials by Country for EFLORNITHINE HYDROCHLORIDE
Location Trials
United States 269
Canada 13
Congo 10
Congo, The Democratic Republic of the 8
Germany 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for EFLORNITHINE HYDROCHLORIDE
Location Trials
California 13
Texas 13
Missouri 11
Florida 11
Minnesota 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for EFLORNITHINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for EFLORNITHINE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 3
Phase 3 10
Phase 2/Phase 3 4
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for EFLORNITHINE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 18
Recruiting 9
Active, not recruiting 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for EFLORNITHINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for EFLORNITHINE HYDROCHLORIDE
Sponsor Trials
National Cancer Institute (NCI) 17
Giselle SaulnierSholler 6
Drugs for Neglected Diseases 5
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for EFLORNITHINE HYDROCHLORIDE
Sponsor Trials
Other 66
NIH 17
Industry 14
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.